Table 2 Patient reactions post first and second COVID-19 vaccine doses
From: Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines
Following Dose 1 | |||
|---|---|---|---|
(n = 38) | SLE | RA | |
Mean ± SD time (hrs) for reaction onset | 26.0 ± 16.2 | ||
Swelling at the site | 6 | 4(66.7) | 2 (33.3) |
Abscess formation at the site | 0 | 0 (0.0) | 0 (0.0) |
Severe pain at the site | 15 | 8 (53.3) | 7 (46.7) |
Fever/chills | 6 | 5 (83.3) | 1 (16.7) |
Allergies | 0 | 0 (0.0) | 0 (0.0) |
Diarrhoea | 1 | 1 (100) | 0 (0.0) |
Nausea/vomiting | 2 | 2 (100) | 0 (0.0) |
Seizures | 0 | 0 (0.0) | 0 (0.0) |
Tingling sensation/numbness in the limbs | 1 | 0 (0.0) | 1 (100) |
Weakness in any part of the body | 7 | 3 (42.9) | 4 (57.1) |
Headaches | 12 | 10 (83.3) | 2 (16.7) |
Cytopenia | 0 | 0 (0.0) | 0 (0.0) |
Chest pain/tightness/breathlessness | 3 | 3 (100) | 0 (0.0) |
Arthralgia/arthritis | 2 | 0 (0.0) | 2 (100) |
Others, e.g., body itches, sweating | 4 | 1 (25.0) | 3 (75.0) |
Hospitalisations due to reaction | 0 | 0 (0.0) | 0 (0.0) |
Following Dose 2 | |||
Mean ± SD time (hrs) for reaction onset 29.2 ± 16.5 | |||
Swelling at the site | 2 | 2 (100) | 0 (0.0) |
Abscess formation at the site | 1 | 0 (0.0) | 1 (100) |
Severe pain at the site | 5 | 3 (60.0) | 2 (40.0) |
Fever/chills | 2 | 2 (100) | 0 (0.0) |
Allergies | 2 | 2 (100) | 0 (0.0) |
Diarrhoea | 0 | 0 (0.0) | 0 (0.0) |
Nausea/vomiting | 1 | 0 (0.0) | 1 (100) |
Seizures | 0 | 0 (0.0) | 0 (0.0) |
Tingling sensation/numbness in the limbs | 1 | 0 (0.0) | 1 (100) |
Weakness in any part of the body | 3 | 1 (33.3) | 2 (66.7) |
Headaches | 6 | 5 (83.3) | 1 (16.7) |
Cytopenia | 0 | 0 (0.0) | 0 (0.0) |
Chest pain/tightness/breathlessness | 4 | 2 (50.0) | 2 (50.0) |
Arthralgia/arthritis | 0 | 0 (0.0) | 0 (0.0) |
Others, e.g., body itches, sweating | 6 | 4 (66.7) | 2 (33.3) |
Hospitalisations due to reaction | 0 (0.0) | 0 (0.0) | 0 (0.0) |